Sodium hydrogen N-(1-oxododecyl)-L-glutamate

Endpoint summary

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

1 200 mg/kg bw/day

Study duration:

subchronic

Species:

rat

Quality of whole database:

Although the study has some restrictions, it is considered to fulfill basic requirements of data reporting.

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

No studies investigating the repeated dose toxicity of Sodium hydrogen N-(1-oxododecyl)-L-glutamate (CAS No. 29923-31-7) are available. Thus, available data for the source substance N-cocoacyl glutaminic acid, sodium salts (CAS 68187 -30 -4) was used in a read-across approach.

The read across is considered valid as the target substance is the major component, and the central member of an homologous series of components, of the source substances, possessing identical functional groups and extremely similar structures.  It is reasonable to expect that the toxicological properties of the target and source substances will not be markedly different.  On this basis, experimental data on the source substances are expected to be directly applicable to the target substance, and can be used to adequately predict its properties. Further details are provided in the in the field “Attached documents”.

The repeated dose toxicity has been investigated in male albino rats.

In the read across Key study the animals received 0 or 1200 mg/kg bw per day for a treatment period of 112 days. No mortality or clinical signs were observed during treatment. The body weight development statistically did not differ between dose and control group. After necropsy the following parameters were assessed: relative organ weights of liver, kidneys, testes, adrenals, spleen. The following clinical chemical and hematological parameters were: hemoglobin, total serum protein, total liver protein, ascorbic acid in adrenals, testes and liver tissue. All values were statistically not different between control and dose groups or were within historical controls. The authors conclude that the NOAEL is 1200 mg/kg bw.

Although the read across Key study has its restrictions in terms of documentation and parameters assessed, the result reflects the fact that during hydrolysis the test substance forms two physiological cleavage products: Coco fatty acids and glutamic acid. Both are natural constituents of conventional foods which are consumed on a gram per day level. Under these circumstances it is unjustified to repeat the subchronic study in order to fill potantial data gaps (histopathology, missing organ weights and clinical chemical and hematological parameter, missing female animals). Therefore, the NOAEL of 1200 mg/kg bw is considered to be a valid point of departure.